The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

University of Cincinnati receives $2.3M from NCI to visualize CAR T cells within the body

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The University of Cincinnati Cancer Center was granted $2.3 million from NCI to develop a technique to visualize where genetically modified immune cells go in the body after being administered to patients with cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Podcast

Anthony Letai reflects on Year One as NCI Director: “The NCI is in business”

“I don’t know of a single grant that left my desk that was not approved and funded,” NCI Director Anthony G. Letai said on this episode of The Cancer Letter Podcast. https://open.spotify.com/episode/2PFYGwliBDYEbxBXFd9MtB?si=95DNBAy0QGSKBX31_uETEA This episode is available on Spotify, Apple Podcasts, and Youtube. Letai recapped his first year as NCI director in conversation with Paul Goldberg,...

Conversation with The Cancer Letter

With Year One metrics in hand, Letai is ready to “bring it home” in Year Two
“I hope I don’t see any more reports of NCI cutting funding, because it just is not consistent with the facts”

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
By Paul Goldberg
Clinical Roundup

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account